ScreenerHero

CAICaris Life Sciences, Inc.

Partial data
NAS · US · Healthcare · Biotechnology · carislifesciences.com
31.47USD+76.70%Mkt Cap: 8.90B $P/E: 3.28

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare usin…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$130.53BUSDP/E 30.0
REGN
Regeneron Pharmaceuticals, Inc.
$82.77BUSDP/E 19.9
MRNA
Moderna, Inc.
$72.88BUSD
ARGX
argenx SE
$57.82BUSDP/E 37.5
ARGX
argenx SE
$59.94BUSDP/E 36.7
UCB
UCB SA
$44.25BUSDP/E 18.9
ONC
BeOne Medicines AG
$41.64BUSDP/E 65.8
RVMD
Revolution Medicines, Inc.
$41.34BUSD
RPRX
Royalty Pharma plc
$33.81BUSDP/E 31.5
ALNY
Alnylam Pharmaceuticals, Inc.
$33.67BUSDP/E 43.8
ROIV
Roivant Sciences Ltd.
$27.61BUSD
INSM
Insmed Incorporated
$26.38BUSD
INCY
Incyte Corporation
$25.73BUSDP/E 16.2
BNTX
BioNTech SE
$25.34BUSD
GMAB
Genmab A/S
$21.66BUSDP/E 28.0
GMAB
Genmab A/S
$20.41BUSDP/E 27.6
ASND
Ascendis Pharma A/S
$15.63BUSDP/E 18.5
JAZZ
Jazz Pharmaceuticals plc
$15.62BUSDP/E 16.5
EXEL
Exelixis, Inc.
$14.41BUSDP/E 18.3
SMMT
Summit Therapeutics Inc.
$13.66BUSD

Key Statistics

Company
Market Cap8.90B $
Enterprise Value4.66B $
Revenue (TTM)907.29M $
Gross Profit539.17M $
Net Income (TTM)-68.09M $
Revenue/Share3.963 USD
Last Price31.47 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)3.28
P/E (Forward)48.86
PEG—
EV/EBITDA36.12
EV/Revenue5.14
P/S5.57
P/B8.51
EPS (TTM)-2.85
EPS (Forward)0.37
52W Range
14.1961% of range42.50
52W High42.50 USD
52W Low14.19 USD
Profitability
Gross Margin66.40%
Oper. Margin2.44%
EBITDA Margin14.22%
Profit Margin-8.38%
ROE-11.79%
ROA-6.05%
Growth
Revenue Growth78.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF83.16M $
CapEx (TTM)16.26M $
FCF Margin11.25%
FCF Yield1.15%
Net Debt-392.50M $
Net Debt/EBITDA-3.04
Balance Sheet
Debt/Equity0.74
Current Ratio7.05
Quick Ratio6.35
Book Value/Sh2.100 USD
Cash/Share2.913 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.42 USD
Upside (mean)-12.9%
Target Range21.00 USD – 36.00 USD
$21.00-12.9% to mean$36.00
# Analysts12
Ownership
Shares Out.282.68M
Float103.39M
Insiders48.51%
Institutions56.67%
Short Interest
Short Ratio4.2d
Short % Float10.10%
Short % Out.4.12%
Shares Short11.64M
Short (prev mo.)11.75M
Technical
SMA 5017.24 (+82.5%)
SMA 20022.91 (+37.4%)
Beta—
S&P 52W Chg20.11%
Avg Vol (30d)2.96M
Avg Vol (10d)3.60M
Technical Indicators
RSI (14)50.6
MACD0.3176
MACD Signal0.3009
MACD Hist.+0.0167
BB Upper19.23 USD
BB Middle17.82 USD
BB Lower16.42 USD
BB Width15.79%
ATR (14)1.154 USD
Vol Ratio (20d)0.84x